A Library-Based Screening Strategy for the Identification of DARPins as Ligands for Receptor-Targeted AAV and Lentiviral Vectors by Hartmann, Jessica et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
A Library-Based Screening Strategy for the Identification of DARPins as
Ligands for Receptor-Targeted AAV and Lentiviral Vectors
Hartmann, Jessica; Münch, Robert C; Freiling, Ruth-Therese; Schneider, Irene C; Dreier, Birgit;
Samukange, Washington; Koch, Joachim; Seeger, Markus A; Plückthun, Andreas; Buchholz, Christian J
Abstract: Delivering genes selectively to the therapeutically relevant cell type is among the prime goals
of vector development. Here, we present a high-throughput selection and screening process that identifies
designed ankyrin repeat proteins (DARPins) optimally suited for receptor-targeted gene delivery using
adeno-associated viral (AAV) and lentiviral (LV) vectors. In particular, the process includes expression,
purification, and biotinylation of the extracellular domains of target receptors as Fc fusion proteins in
mammalian cells and the selection of high-affinity binders by ribosome display from DARPin libraries
each covering more than 10 variants. This way, DARPins specific for the glutamate receptor subunit
GluA4, the endothelial surface marker CD105, and the natural killer cell marker NKp46 were gener-
ated. The identification of DARPins best suited for gene delivery was achieved by screening small-scale
vector productions. Both LV and AAV particles displaying the selected DARPins transduced only cells
expressing the corresponding target receptor. The data confirm that a straightforward process for the
generation of receptor-targeted viral vectors has been established. Moreover, biochemical analysis of a
panel of DARPins revealed that their functional cell-surface expression as fusion proteins is more relevant
for efficient gene delivery by LV particles than functional binding affinity.
DOI: https://doi.org/10.1016/j.omtm.2018.07.001
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-153188
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Hartmann, Jessica; Münch, Robert C; Freiling, Ruth-Therese; Schneider, Irene C; Dreier, Birgit; Samukange,
Washington; Koch, Joachim; Seeger, Markus A; Plückthun, Andreas; Buchholz, Christian J (2018). A
Library-Based Screening Strategy for the Identification of DARPins as Ligands for Receptor-Targeted
AAV and Lentiviral Vectors. Molecular Therapy - Methods Clinical Development, 10:128-143.
DOI: https://doi.org/10.1016/j.omtm.2018.07.001
Original Article
A Library-Based Screening Strategy for the
Identification of DARPins as Ligands for
Receptor-Targeted AAV and Lentiviral Vectors
Jessica Hartmann,1 Robert C. Münch,1 Ruth-Therese Freiling,1 Irene C. Schneider,1 Birgit Dreier,2
Washington Samukange,1 Joachim Koch,3 Markus A. Seeger,4 Andreas Plückthun,2 and Christian J. Buchholz1
1Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, 63225 Langen, Germany; 2Department of Biochemistry, University of Zurich, 8057 Zurich, Switzerland;
3Institute of Medical Microbiology and Hygiene, University of Mainz Medical Center, 55131 Mainz, Germany; 4Institute of Medical Microbiology, University of Zurich,
8006 Zurich, Switzerland
Delivering genes selectively to the therapeutically relevant cell
type is among the prime goals of vector development. Here, we
present a high-throughput selection and screening process that
identiﬁesdesigned ankyrin repeat proteins (DARPins)optimally
suited for receptor-targeted gene delivery using adeno-associ-
ated viral (AAV) and lentiviral (LV) vectors. In particular, the
process includes expression, puriﬁcation, and in situ bio-
tinylation of the extracellular domains of target receptors as Fc
fusion proteins in mammalian cells and the selection of high-af-
ﬁnity binders by ribosome display from DARPin libraries each
covering more than 1012 variants. This way, DARPins speciﬁc
for the glutamate receptor subunit GluA4, the endothelial sur-
face marker CD105, and the natural killer cell marker NKp46
were generated. The identiﬁcation of DARPins best suited for
gene delivery was achieved by screening small-scale vector pro-
ductions. Both LV and AAV particles displaying the selected
DARPins transduced only cells expressing the corresponding
target receptor. The data conﬁrm that a straightforward process
for the generation of receptor-targeted viral vectors has been es-
tablished.Moreover, biochemical analysis of a panel ofDARPins
revealed that their functional cell-surface expression as fusion
proteins is more relevant for efﬁcient gene delivery by LV parti-
cles than functional binding afﬁnity.
INTRODUCTION
Genetic modiﬁcation of cells has become one of the most important
technologies not only in basic life science but also in gene therapy.
From a portfolio of gene delivery vehicles, lentiviral (LV) vectors
and vectors derived from adeno-associated virus (AAV) are most
often used. Whereas LVs stably integrate their genetic information
into the genome of the transduced cells, AAV vectors remain
episomal.1 Therefore, AAVs are better suited for terminally differen-
tiated cells or if short-term gene expression in dividing cells is
required, whereas LVs are preferred when stem cells or dividing cells
need to be genetically modiﬁed.
Regardless which type of gene delivery vehicle is used, the main goal
for gene transfer is to deliver genetic information with high efﬁciency
precisely to the therapeutically relevant cell type of interest not only
ex vivo in cell culture, but also in vivo after local or systemic admin-
istration. Attempts to tackle this challenge focus on restricting trans-
gene expression either by altering regulatory sequences within the
vector genome2 or by modifying cell entry features through vector
surface engineering.3,4 Vector surface engineering controls the ﬁrst
step in gene transfer, the binding of the vector particle to its cell-sur-
face receptor. Several approaches have been developed to modify the
interaction of the vector particles with cell-surface receptors,
including designed ankyrin repeat protein (DARPin) adaptors
bridging between adenoviruses and target receptors,5,6 permanent
modiﬁcation of viral capsids, or envelope proteins by incorporation
of receptor-binding moieties or evolution-based engineering strate-
gies.7 A complete re-direction of LV vectors to rare target cell popu-
lations with low or even absent off-target activity on non-target cells
was achieved by permanent ablation of natural receptor binding and
genetic fusion of a targeting ligand that binds the extracellular part of
the selected target receptor with high afﬁnity to the vector surface.8
This engineering concept has been successfully implemented for en-
velope glycoproteins from Sindbis virus,9,10 Tupaia virus,11 measles
virus (MV),12 and recently Nipah virus (NiV)13 that have the recep-
tor-attachment and membrane-fusion functions separated onto two
glycoproteins.
Although fundamentally different in their physical properties, this
rational engineering concept is applicable also to non-enveloped
AAV particles.14,15 Whereas single-chain antibodies (scFvs) have
been mainly used as targeting ligands for LV vectors, these molecules
are not applicable to AAV vectors as genetic fusion, because they are
not compatible with the assembly of the AAV particles under
reducing conditions in the cell nucleus. DARPins, in contrast, can
be used for receptor-targeting of LV, AAV, adenoviral (AdV), and
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oncolytic MV vectors.8,16,17 Notably, this way such different vector
types as LV and AAV can be generated in a way to use an identical
binding domain for cell entry.14,15,18
Adapted from naturally occurring ankyrin repeat proteins, DARPins
are based on small (14–17 kDa), highly stable, a-helical scaffolds with
a very low tendency to aggregate.19 By diversifying seven residues
within each repeat domain (33 amino acids) and by combining 2–3
repeats ﬂanked by short N- and C-terminal capping modules, combi-
natorial DARPin libraries covering more than 1012 variants have been
generated.20,21 The ﬁrst combinatorial DARPin library was based on
consensus design utilizing a database with a large number of unbiased
ankyrin repeat protein sequences.20 Subsequently, this design was
improved by introducing point mutations into the C-terminal
capping module to stabilize the DARPins, while the remaining frame-
work remained unchanged.22 The design by Seeger et al.21 encom-
passes one additional diversiﬁed position in each repeat domain
and three diversiﬁed positions in the C-terminal capping module
and changes in the overall framework ending up in a DARPin library
with reduced hydrophobicity and an extended randomized surface.
Using ribosome display, DARPins binding to basically any protein
of interest with afﬁnities in the range of antibodies can be obtained.23
Ribosome display is an in vitro evolution process in which the
DARPin (phenotype) is physically coupled to its genetic information
(genotype) within the ribosome.24 This is achieved by forming stable
ternary complexes of the encoding mRNA, the ribosome, and the
nascent DARPin polypeptide chain. Notably, libraries covering very
large repertoires of DARPin variants can be selected by this approach,
since the whole process operates cell free. Accordingly, the selection
process usually results in a diverse pool of target-binding DARPins
from which the best candidates have to be identiﬁed individually.23
We report here proof of principle for a selection process that inte-
grates the screening in context of vector particles and thus identiﬁes
DARPins suitable for receptor-targeted AAV and LV particles. Cho-
sen target receptors included the glutamate receptor subunit GluA4, a
marker for a subpopulation of inhibitory interneurons being highly
relevant for various neurological disorders such as epilepsy,25 the acti-
vating natural killer (NK) cell receptor NKp46,26 a ubiquitous NK cell
marker, and endoglin (CD105), a marker for tumor-related angiogen-
esis.27 These served as target for the selection of various DARPin
libraries, including two newly generated libraries, each covering
more than 1012 variants optimized for straightforward subcloning
into viral vector packaging plasmids. Of the pools of DARPins
selected for each target receptor, those best suited for cell-type-spe-
ciﬁc gene transfer with LV or AAV were identiﬁed. Biochemical anal-
ysis of the DARPins revealed correlations among functional target
receptor binding afﬁnity, cell-surface expression levels when fused
to an LV envelope protein, and gene delivery. Taken together, the
data provide proof of concept for a high-throughput approach of
selecting and identifying targeting ligands for viral vectors and pro-
vide some insights into distinct requirements of DARPins for LV
and AAV re-targeting.
RESULTS
The process for the selection of DARPins compatible with receptor
targeting of AAVs and LVs is shown in Figure 1. For straightfor-
ward puriﬁcation, the extracellular part of the target receptor is
Figure 1. Workflow for the Selection of DARPins for
Receptor-Targeted LVs and AAVs
DARPin selection by ribosome display is shown in steps 1
and 2. All substeps of the ribosome display cycle are
performed cell-free in vitro. Each cycle begins with the
transcription and translation of a DARPin-encoding DNA
library, flanked by a T7 promoter (T7), a ribosome binding
site (RBS), and a spacer sequence. Ternary complexes of
ribosome, the DARPin-encoding mRNA, and the trans-
lated polypeptide (shown in identical color) are formed and
allowed to bind to the target protein during the selection
process. The selection process encompasses three
steps: pre-panning, counter-, and target selection. Pre-
panning and counter-selection results in the elimination of
the black and brown DARPins binding to the Fc domain or
streptavidin used for immobilization of the target receptor.
The green DARPin, in contrast, binds the target receptor
and is carried forward to the next selection cycle. After the
selection process, unbound complexes are washed away
before elution, and reverse transcription of the mRNA is
carried out. The cDNA fragments are PCR amplified and
ligated to the upstream and downstream flanking se-
quences. The PCR-amplified ligation product is used as template library for the next ribosome display cycle or cloned into an expression vector for analysis of single clones on
the protein level. After ribosome display, individual DARPin molecules are expressed as crude E. coli lysates (step 3), tested for their receptor binding ability (step 4), and
subcloned into the corresponding viral vector plasmids (step 5) before small-scale generation of DARPin-displaying LV or AAV particles (step 6), which are finally analyzed for
cell-type-specific gene transfer (step 7). Exemplarily an AAV vector is shown displaying five molecules of an individual DARPin clone on its surface, but the same procedure is
applied for LV particles. Step 1 of the figure is adapted from Dreier and Plu¨ckthun.53
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expressed in HEK293T cells fused to the fragment crystallizable (Fc)
domain of immunoglobulins. Biotinylation of the expressed target
receptor is performed during production in HEK293T cells.28
Importantly, the used DARPin libraries contain compatible restric-
tion sites to allow easy subcloning into the viral vector coat protein
plasmids. After initial ribosome-display-based binder selection,
target receptor binding is veriﬁed by ELISA or ﬂow cytometry
followed by downstream screening steps involving small-scale
high-throughput compatible production of vector particles in
multi-well plates and transduction of target-receptor positive and
negative cell lines. Notably, during ribosome display, DARPins
binding to the Fc part of the recombinant target receptor or to
biotin are removed through pre-panning and counter-selection
steps (Figure 1).
Construction of DARPin Libraries Optimized for Viral Vector
Display
To enable a fast and efﬁcient selection process and subsequent incor-
poration into viral vectors, we generated two DARPin libraries that
were optimized for translation in E. coli and harbor unique restriction
sites compatible with our vector-targeting platform. The viral vector
(VV) compatible DARPin libraries VV-N2C and VV-N3C were
assembled from de novo synthesized DNA fragments encoding the
diversiﬁed ankyrin repeats as well as the N- and C-terminal capping
modules based on previously published DARPin library sequences.23
Upon subsequent ligation and PCR ampliﬁcation, we generated
DARPin libraries consisting of two (VV-N2C) and three (VV-N3C)
diversiﬁed repeats in-between the constant N- and C-capping mod-
ules, respectively (Figure S1). Each DARPin library covered at least
1012 DARPin molecules, after ligation of the ﬂanking regions needed
for ribosome display to the assembled library as estimated from the
amount of ligated DNA before PCR ampliﬁcation (Table S1).
Sequence analysis of 100 clones of each library revealed a constant
framework with incidental point mutations but no frameshifts,
harboring seven diversiﬁed amino acid positions within each ankyrin
repeat for 81% (VV-N2C) and 60% (VV-N3C) of the clones
(Figure S2).
Selection of GluA4-Specific DARPins
GluA4 is composed of an extracellular amino-terminal domain
(ATD), an extracellular ligand-binding domain, a transmembrane
domain, and an intracellular carboxyl-terminal domain.29 For the
DARPin selection process, the ATD of murine GluA4 was fused to
the constant region of human immunoglobulin G1 (huIgG1-Fc)
and an Avi tag, resulting in GluA4-Fc (Figure 2A). As control, the
huIgG1-Fc fused to the Avi tag (Fc) was generated (Figure 2A). The
proteins were produced in a biotinylated and unbiotinylated form
by expression in HEK293T cells transfected with a plasmid encoding
the E. coli-derived biotin ligase BirA, an enzyme enabling speciﬁc bio-
tinylation of the Avi tag in the presence of biotin and ATP.28 GluA4-
Fc and Fc were puriﬁed to homogeneity from the culture medium by
protein A afﬁnity puriﬁcation and subsequent preparative size exclu-
sion chromatography resulting in approximately 1 mg of pure protein
from 108 cells. The GluA4-Fc protein consisted mainly of tetramers,
and, to a lesser extent, of dimers and larger oligomers (Figure 2B).
This reﬂects the tetrameric structure of glutamate receptors build
from dimers.30 The Fc protein solely formed disulﬁde-linked homo-
dimers (Figure 2B). All of the oligomers disassembled to monomers
under denaturing and reducing conditions (Figure 2C). Only the pro-
teins produced by BirA-expressing HEK293T cells were detectable by
streptavidin (Figure 2C). Roughly 76% of GluA4-Fc protein and 63%
of the Fc protein produced in the presence of BirA ligase were bio-
tinylated as determined by ELISA using a biotinylated reference
standard.
GluA4-Fc was then used to select DARPins speciﬁc for GluA4 from
the newly generated VV-N2C and VV-N3C libraries as well as from
the N3C DARPin library with reduced hydrophobicity (S-N3C).21
Speciﬁc DARPins were isolated from these libraries by performing
ﬁve ribosome display selection rounds against the tetrameric
GluA4-Fc molecule, including pre-panning steps against neutravi-
din or streptavidin as well as counter-selection steps against Fc
and biotin to prevent the selection of unspeciﬁc or Fc-speciﬁc
binders. For further screening, individual DARPins from the
selected pools were expressed in E. coli (Figure S3A) and then
Figure 2. Expression and Purification of
Recombinant Target Proteins for Ribosome Display
(A) Schematic drawing of GluA4-Fc and Fc, two recom-
binant proteins used as targets for ribosome display. The
GluA4-Fc construct consists of the amino-terminal
domain (ATD) of the glutamate receptor subunit 4 (GluA4)
fused N-terminally to the Ig kappa chain signal peptide
(SP) and C-terminally to the constant region of human
IgG1 (huIgG1-Fc) for detection and purification and an Avi
tag for biotinylation. As control in selections, only huIgG1-
Fc with Avi tag were expressed (directly fused to the signal
peptide). (B) Chromatograms of size exclusion chroma-
tography (SEC) of proteins expressed in and purified from
the cell culture supernatant of HEK293T cells via protein
A. The calculated molecular weight of the corresponding
peaks is indicated. (C) Reducing SDS-PAGE and western blot analysis of SEC-purified GluA4-Fc and Fc proteins produced in the absence () or presence of biotin (+) added
to the culture. 2 mg and 20 ng of purified proteins were loaded onto 10% SDS gels, respectively. Purified proteins were visualized by PageBlue protein staining solution and
detected by a huIgG1-Fc-specific antibody. Biotinylated proteins were detected using streptavidin-HRP.
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assessed for binding to GluA4-Fc and to Chinese hamster ovary
(CHO)-GluA4 cells directly from crude bacterial lysates. This way,
we identiﬁed 12 candidates that bound efﬁciently to GluA4-Fc
and CHO-GluA4 cells, but not to GluA4-negative CHO cells or re-
combinant Fc (Figures 3 and S3B).
GluA4-DARPins Mediate Gene Transfer of LV and AAV Vectors
In order to evaluate the capacity of the selected DARPins to re-
direct the tropism of LV and AAV vectors to GluA4, they were
fused to the H protein of MV and the VP2 protein of AAV-2 for
pseudotyping of LV and AAV vectors, respectively. The targeting
potential of the corresponding LV and AAV vector particles was
determined by transduction of GluA4-positive and negative CHO
cells (CHO-GluA4 and CHO-K1). As negative control, the epithelial
cell adhesion molecule (EpCam)-speciﬁc DARPin Ec131 was used
for both LV and AAV vectors,14 while as positive control the sin-
gle-chain Fv (scFv) recognizing GluA4 and GluA2 (Fab7) was
applied to LV vectors only.12 Unmodiﬁed AAV-2 particles or LV
particles pseudotyped with VSV-G were used as controls. For
AAV particles, six out of the 12 DARPin candidates (SC5, SD7,
SD8, 2A2, 2K19, SK14) generated more than 10% transduced
CHO-GluA4 cells. This rate was clearly above the 5% background
transduction rate observed with the control DARPin or on CHO-
K1 cells with all DARPins tested (Figure 4A). Notably, none of
the selected DARPin-mediated transduction of CHO-K1 cells above
the background level. However, only DARPins SD8, SK14, and
2K19 mediated a signiﬁcantly enhanced transduction of target
compared to non-target cells. Among these, 2K19 mediated the by
far highest transduction rate with AAV (Figure 4A).
For LV particles, background transduction was in general much lower
than with the AAV vectors (Figure 4). Six DARPin candidates (SB4,
SK14, 2A2, 2B7, 2G10, and 2K19) mediated signiﬁcantly enhanced
and selective transduction of the CHO-GluA4 cells compared to
CHO-K1 (Figure 4B). Notably, at least two DARPins (SB4 and
SK14) were more efﬁcient in mediating gene transfer than the scFv
Fab7. Overall, the most effective DARPins for re-targeting of LV par-
ticles were SB4, SK14, and 2K19, whereas for AAV particles, SD8,
SK14, and 2K19 were the best candidates. Interestingly, only two
DARPins (2K19 and SK14) mediated efﬁcient gene transfer for
both LV and AAV particles.
To demonstrate that cell entry was indeed mediated by the DARPins,
vector stocks were pre-incubated with recombinant GluA4-Fc or Fc
protein prior to transduction of target and non-target cells. Pre-incu-
bation with GluA4-Fc resulted in complete abrogation of speciﬁc gene
transfer on CHO-GluA4 cells for both AAVs and LVs (Figures 4C,4D,
and S4). In contrast, pre-incubation with Fc protein had no inﬂuence
on the transduction efﬁciency, which was then comparable to that
observed with untreated vector stocks.
GluA4-DARPin-Displaying Vectors Are Highly Target Specific
After identiﬁcation of the most effective DARPins for LV and AAV
retargeting, we next assessed their receptor speciﬁcity by transducing
cell lines expressing the closely related family members GluA1–3 or
the non-related kainate receptor GluR6 (Figures 5 and S5). None of
the vector stocks displaying the selected DARPins mediated speciﬁc
gene transfer of cells expressing GluA1–3 or GluR6, while efﬁcient
gene transfer of CHO-GluA4 was demonstrated (Figures 5 and S5).
In contrast, the LV vector displaying the Fab7-scFv transduced
CHO-GluA4 and CHO-GluA2 cells (Figures 5B and S5C). These
data demonstrate that the selected DARPins can readily discriminate
between GluA4 and its closely related family members.
Selected DARPins Bind to GluA4 with High Affinity
Next, we characterized the selected DARPins at the molecular level.
Their sequences are aligned in Figure S6. Whereas 2K19 as well as
2A2, 2A10, 2B7, and 2G10 were derived from the VV-N2C library,
SK14 as well as SA8, SB4, SC5, SD6, SD7, and SD8 were derived
from the S-N3C DARPin library. Interestingly, DARPin 2K19 is
an N1C DARPin comprised of only one single repeat domain be-
sides the capping domains. Next, two DARPins (2K19 and SK14)
with the most favorable targeting properties for both LV and
AAV vectors as well as SD8, which only mediated gene transfer
for AAV, were expressed in E. coli and puriﬁed to homogeneity
for further investigations (Figures 6A and S7). In the next step,
the apparent binding afﬁnity to GluA4 was estimated by ELISA.
The selected DARPins bound to GluA4 with high afﬁnity in the
lower nanomolar range (KD < 5 nM). The receptor speciﬁcity was
determined on cell lines expressing GluA4, GluA1, GluA2, or
GluA3. All three selected DARPins bound to CHO-GluA4 cells
and showed no cross-reactivity to GluA1 and GluA3 or the parental
CHO-K1 cell line (Figure 6B). Interestingly, DARPins SD8 and
2K19 explicitly recognized GluA4, whereas SK14 bound CHO-
GluA2 cells as well, even though to a lower, not signiﬁcantly
enhanced extent (Figure 6B). Although SK14 was able to bind to
GluA2, it did not mediate gene transfer via this receptor when dis-
played on LV or AAV vectors (Figure 5).
Figure 3. Identification of DARPin Clones Binding to
Cell-Surface-Exposed GluA4
Crude E. coli extracts of randomly picked clones obtained
as output of the ribosome display selection procedure
were analyzed for binding to GluA4-positive and -negative
CHO cells (CHO-GluA4 and CHO-K1) via flow cytometry.
The percentage of cells bound by the DARPin clone is
shown. E. coli extracts without DARPin were used as
control (ctl). Arrows indicate selected DARPins used for
further analysis. See also Figure S3.
www.moleculartherapy.org
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Binding and Surface-Expression Properties Define the
Suitability of a DARPin as a Targeting Ligand
Since not all GluA4-binding DARPins mediated gene transfer by LV
and/or AAV, we next evaluated biochemical parameters of the
DARPin fusion constructs and vectors. On vector particles, DARPins
are displayed as fusion protein, in conjunction with theMVH protein
for LV, and the VP2 protein for AAV vectors. For incorporation into
LV particles, the DARPin-H fusion protein has to be efﬁciently ex-
pressed at the cell surface. To assess the surface expression of the
DARPin-H constructs, HEK293T cells were transfected with the cor-
responding expression plasmids and analyzed for protein presenta-
tion by ﬂow cytometry utilizing the His tag present on the MV H
fusion protein (Figures 7A and S8). Out of 10 tested DARPin-H con-
structs, DARPins SK14, SB4, 2K19, 2B7, SD8, SD7, and SC5 showed
Figure 4. Identification of GluA4-Specific DARPins
Mediating Transduction by AAV and LV Vector
Particles
The identified GluA4-binding DARPins were cloned into
the expression plasmids pDARPin-VP2 as well as pCG-
HD18-DARPin, which were used to produce GluA4-tar-
geted AAV and LV particles in small-scalemulti-well plates
in a total volume of 750 mL, respectively. (A and B) CHO-
GluA4 and CHO-K1 cells were incubated with 50 mL AAV
(A) or 50 mL LV (B) particles encoding GFP. Cells were
analyzed 72 hr after transduction by flow cytometry. Un-
transduced (ut) cells and AAV particles displaying the
EpCAM-specific DARPin Ec1 were used as negative
control. Unmodified AAV particles (AAVwt) were used as
positive control. For LVs, particles displaying the scFv
Fab7 or pseudotyped with VSV-G were used as positive
control. Each transduction experiment was performed at
least three times with individually produced vector stocks.
For all experiments, the mean and SD are shown.
****p% 0.0001; ***p% 0.001; **p% 0.01; *p% 0.05; ns,
not significant by unpaired t test comparing target versus
non-target cells per vector sample. (C and D) For the best
performing AAV (C) and LV (D) particles a competition
assay was performed by incubation of the vector particles
with recombinant GluA4-Fc and Fc proteins, respectively,
or buffer as control prior to transduction of CHO-K1 or
CHO-GluA4 cells. In all experiments, the cells were
analyzed for GFP expression 72 hr post-transduction by
flow cytometry. Untransduced cells and AAV particles
displaying the EpCAM-specific DARPin Ec1 were used as
negative controls. Each transduction experiment was
performed at least three times with individually produced
vector particles, showing mean values and SDs.
****p% 0.0001; ***p% 0.001; **p% 0.01; *p% 0.05; ns,
not significant by one-way ANOVA comparing each con-
dition with each other per vector sample (Tukey’s multiple
comparisons test). See also Figure S4.
high surface-expression rates within a similar
range (mean ﬂuorescence intensity [MFI] of
815 to 1,417). Two DARPins (SD6 and 2G10)
resulted in substantially weaker surface expres-
sion (MFI of 154 to 213), in the range of that
of the scFv Fab7 fused to the H protein, and only one DARPin
(2A10) was not detectable at all (Figures 7A and S9C). Notably, anal-
ysis of the particle composition by western blot revealed a clear pos-
itive correlation between surface expression and incorporation of the
DARPin-H proteins into LV vector particles (Figure S9A).
Next, we evaluated the ability of the corresponding LV vectors to
transduce cells independently of binding to the GluA4 receptor. For
this purpose, we made use of a His tag C-terminally fused to the
DARPin and CHO cells expressing a membrane-bound form of the
anti-His scFv 3D532 (CHO-aHis cells). Transduction of CHO-aHis
cells with DARPin-LV particles demonstrated efﬁcient to moderate
gene transfer rates for DARPins with a high surface expression
(Figures 7B and S9). DARPins that exhibited weak or no detectable
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surface expression as H fusion protein mediated no or very few trans-
duction events. These results reveal a correlation between the amount
of incorporated DARPin-H protein and the cell fusion activity of the
LV particles on CHO-aHis cells. When directly comparing the gene-
transfer rates on CHO-GluA4 and CHO-aHis cells, we can
distinguish three groups of DARPins. DARPins SD8, SD7, and SC5
mediated high to moderate gene transfer on CHO-aHis cells but
did not, or only inefﬁciently, transduce CHO-GluA4 cells. DARPins
SK14, SB4, and 2K19 efﬁciently transduced both CHO-aHis and
CHO-GluA4 cells, while 2A10, SG10, and SD6 were basically inactive
on both cell types.
To assess whether the binding properties of the selected DARPins to
GluA4 were altered by fusion to the MV H protein, we assessed bind-
ing of the DARPin-H proteins presented onHEK293T cells to varying
GluA4-Fc concentrations in a ﬂow-cytometry-based assay. For all
DARPins except 2A10, which showed no surface expression, binding
curves with the typical sigmoidal shape were obtained (Figures 7C
and S8). From these curves, the apparent functional binding afﬁnity,
commonly referred to as avidity, was calculated from the GluA4-Fc
concentrations required for half-maximal binding. For four DARPins
(SD8, SK14, 2K19, 2B7) and the scFv Fab7, these were in the single-
digit nanomolar range (apparent KD = 1.6–3.7 nM) (Figure 7C).
DARPins 2B7 and SB4 were slightly less afﬁne (apparent KD =
8.4 nM and 19 nM). Binding of DARPins SD6, SD7, 2G10, and
SC5 was too close to the detection limit to calculate a meaningful
value. Themaximal MFI obtained in this assay was taken as ameasure
for the functional binding capacity of cell-surface-displayed DARPins
to GluA4. Four DARPins (SB4, SK14, 2B7, and 2K19) showed a rela-
tively high binding capacity, whereas presentation of DARPins SD8,
SD6, SD7, 2G10, SC5, or the scFv Fab7 resulted in a 3.5- to 12-fold
lower binding capacity (Figure 7C).
To analyze which parameters inﬂuence the ability of the selected
DARPins to mediate transduction, the apparent surface-binding
avidity and the functional binding capacity were correlated with the
amount of DARPins presented on the cell surface, respectively. All
four DARPins that mediated efﬁcient gene transfer by LVs cluster
in this diagram and show high surface expression and binding capac-
ity of GluA4 as MV H fusion protein (Figure 7D). In contrast,
DARPins with similar high surface expression but lower GluA4 bind-
ing capacity led only to efﬁcient transduction of CHO-aHis but not of
CHO-GluA4 cells (Figure 7). This suggests that high surface expres-
sion and functional binding capacity are critical for LV vectors, while
strong binding avidity can be beneﬁcial but is not essential. While
these data are obviously more relevant for LVs, it is interesting to
note that the DARPins mediating AAV transduction rather cluster
in the diagram correlating binding avidity with surface expression.
Those DARPins with calculated apparent binding avidity values
of <5 nM mediated transduction by AAV, while the less-afﬁne
DARPins 2B7 and SB4 did not (Figures 4 and 7D).
Having the successful selection of GluA4-speciﬁc DARPins compat-
ible with receptor targeting of AAVs and LVs demonstrated, we next
applied the DARPin selection process for murine CD105, a marker of
endothelial cells, and human NKp46, a receptor on NK cells. For
CD105, the selections were performed using N2C and N3C DARPin
libraries described by Binz et al.,20 here termed B-N2C and B-N3C. In
total, 21 binders were identiﬁed from the subsequent cellular binding
assay and were screened for their ability to mediate gene transfer (Fig-
ures 8A–8C). Eight DARPins, with 2B33 and 3B72 being most efﬁ-
cient, mediated AAV gene transfer substantially above background
into CHO cells overexpressing CD105 (CHO-mCD105) (Figures
8B–8C). For NKp46, selections were performed using the VV-N3C
library as well as with the S-N3C DARPin library. Promising candi-
dates identiﬁed by cellular binding assays were assessed for their sur-
face presentation and binding to recombinant NKp46 upon display
on the MV H protein (Figures 8D and 8E). Eight out of 11 tested
DARPin-H proteins showed a high surface expression, from which
six candidates showed NKp46 binding more than 2-fold over back-
ground (Figure 8E). Five out of ﬁve tested DARPins displaying LVs
mediated gene transfer into HT1080 cells overexpressing NKp46
Figure 5. Recognition of Glutamate Receptor Family Members by GluA4-
Targeted Vector Particles
To determine the selectivity of the GluA4-targeted vector particles, CHO-K1 cells
expressingGluA1-4 or GluR6 aswell as the parental cell line were incubatedwith the
indicated AAV (top panel) and LV (bottom panel) particles, respectively. In all ex-
periments, the cells were analyzed for GFP expression 72 hr post-transduction by
flow cytometry. Untransduced cells, AAV particles displaying the EpCAM-specific
DARPin Ec1 (top panel), or LV particles displaying the GluA2- and GluA4-specific
scFv Fab7 (bottom panel) were used as control. Each transduction experiment was
performed at least three times with individually produced vector particles, showing
mean values, SDs, and p values. ns, not significant; p values by one-way ANOVA
comparing each condition with each other per vector sample (Tukey’s multiple
comparisons test). See also Figure S5.
www.moleculartherapy.org
Molecular Therapy: Methods & Clinical Development Vol. 10 September 2018 133
(HT1080-NKp46) over background (Figure 8F). Four DARPins (3F9,
3A8, 3E7, and 3C9) mediated transduction efﬁciencies above 65%.
Exactly these DARPins demonstrated high surface expression and
receptor binding (Figure 8E).
DISCUSSION
Cell-type-speciﬁc delivery of viral vectors has become an important
tool not only in basic research but also in gene therapy with ﬁrst clin-
ical applications.33 Ablation of natural receptor binding sites and
simultaneous genetic fusion of a receptor-speciﬁc targeting ligand
to the vector surface was demonstrated to be a highly efﬁcient and
ﬂexible method to re-direct vectors.8 DARPins offer several advan-
tages as targeting ligands over antibody scaffolds, because they can
be selected for almost any target protein of choice and exhibit favor-
able properties like high stability, no cysteine bridges, low immuno-
genicity, and low aggregation tendency.17
To work properly as targeting ligand for AAV or LV vector particles,
DARPins have to fulﬁll various requirements. These include (1) bind-
ing to the target receptorwith high selectivity, (2) efﬁcient expression in
mammalian cells as fusion protein with a paramyxoviral attachment
protein or the AAV capsid protein, (3) incorporation into the vector
particles, and (4) mediating cell entry of the vector particle followed
by gene delivery. To selectDARPins recognizing target receptors as dis-
played in their native form on the cell surface, we expressed extracel-
lular parts of the interneuron marker GluA4, the endothelial marker
CD105 or the NK cell marker NKp46 as secreted Fc-fusion proteins
in mammalian cells. Fc tagging usually results in dimerization but
can also be compatible with tetramer formation. Indeed, production
of the Fc fusion protein with theATD ofGluA4 yielded dimers and tet-
ramers which is in line with glutamate receptors being composed of
four subunits, building dimers of dimers and the ATD being respon-
sible for dimer formation.29 However, inclusion of a huge protein tag
like the huFc part or antibodies to capture the target protein during
ribosome display bears the risk of off-target binder selection. To mini-
mize selection of off-target binders, we included several pre-panning
and counter-selection steps during the selection process. This strategy
efﬁciently prevented selection of huFc tag-speciﬁc DARPins while
ensuring enrichment of target-speciﬁc binders. In addition, no capture
antibody was used. Instead, coupling was ensured by binding of bio-
tinylated target protein to neutravidin or streptavidin.
While the target proteins for ribosome display can be biotinylated
in vitro or in vivo, we adapted here the method of metabolic bio-
tinylation in mammalian cells.28,34 In this case, protein biotinylation
is performed simultaneously to its production within mammalian
cells, circumventing additional manipulation of the protein after pu-
riﬁcation. We used an endoplasmic reticulum (ER)-associated and a
secreted form of the E. coli derived BirA ligase during production,
to allow biotinylation of secreted proteins during intracellular traf-
ﬁcking and within the cell culture supernatant. The successful selec-
tion of GluA4- and NKp46-speciﬁc DARPins proves that this
approach is efﬁcient enough to produce target proteins for ribosome
display.
Equally important to the quality of the target protein is the DARPin
library used for the selection. Here, we generated two libraries opti-
mized for straightforward subcloning into viral vector packaging plas-
mids. Each DARPin library covered at least 1012 DARPin molecules
with the expected amino acid sequence and diversiﬁed positions con-
ﬁrming their high quality. DARPins active as targeting ligands were
successfully selected from these newly generated as well as established
DARPin libraries. Notably, 13 of the 13 selected DARPins that bound
GluA4 in ELISA assays also recognized GluA4 in its native conforma-
tion on cells, conﬁrming the quality of the target proteins.
It was previously shown for a panel of well-established Her2-speciﬁc
DARPins that not all DARPins active in binding to a particular target
Figure 6. The Identified GluA4-DARPins Bind GluA4 with High Apparent Affinity
(A) Reducing SDS-PAGE and western blot analysis of His-tagged DARPins purified from E. coli. 2 mg and 500 ng protein were loaded onto a 15% SDS gel, respectively.
Purified proteins were visualized by PageBlue protein staining solution (top) and detected by an anti-His-tag specific antibody (bottom). (B) Binding of graded amounts of
DARPin SD8 (gray circles), SK14 (black diamonds), 2K19 (black squares), and the unrelated DARPin H3B5 (open diamonds) to recombinant GluA4-Fc determined by ELISA.
(C) Binding of purified DARPins to CHO-K1 cells expressing GluA1-4 or the parental cell line analyzed by flow cytometry. The unrelated DARPin H3B5 was used as control.
Mean fluorescent intensity values of three independent experiments represented as bar diagram are shown with mean values and SDs. ****p % 0.0001; ***p % 0.001;
**p % 0.01; ns, not significant by one-way ANOVA comparing each condition with each other per DARPin (Tukey’s multiple comparisons test). (D) Representative flow
cytometry histograms of (C). CHO-GluA1 (gray dotted line), CHO-GluA2 (gray dashed line), CHO-GluA3 (black dashed line), CHO-GluA4 (black solid line), and CHO-K1
(filled curves) cells were either incubated with indicated DARPins or as controls with secondary antibody (2nd Ab) or buffer only (unstained).
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receptor mediate gene delivery by LVs equally well.18 Accordingly, we
set up a screening platform enabling the production of receptor-tar-
geted LV and AAV vectors in a small-scale format, in order to identify
those DARPins that mediate the most efﬁcient viral gene transfer.
Importantly, non-concentrated viral vector supernatant was used to
indirectly assess in addition the inﬂuence of the DARPins on vector
assembly and production yield. In this respect, we could recently
demonstrate that ratios of VP1, VP2, and VP3 in assembled AAV
capsids can vary with the polypeptide fused to VP2 and affect the
overall yield.35 Also for LV particles the DARPin can impact on the
incorporation efﬁciency of the MV H fusion protein with a direct
consequence for the overall amount of transduction-competent par-
ticles (Figures S9A and S9B).18 Interestingly, less than half of the
selected GluA4-DARPins and about one-third of the tested CD105-
DARPins mediated gene transfer of LV or AAV vectors. Only two
GluA4-DARPins (SK14 and 2K19) mediated efﬁcient and speciﬁc
transduction for both vector platforms. In contrast, the GluA4-bind-
ing DARPins SD7 and SD8mediated gene transfer by AAV but not by
LV. Notably, SK14, SD7, and SD8 exhibited very similar binding
characteristics to GluA4 as tested from crude E. coli lysates and
showed comparable surface expression when fused to the MV H pro-
tein. However, for DARPin candidates SD7 and SD8, the ability to
bind to GluA4 got lost upon fusion to MV H, suggesting that target
binding by these DARPins is either incompatible with their C-termi-
nal fusions or they may become inactive through post-translational
modiﬁcations such as glycosylation interfering with target receptor
recognition. For display on LV particles, DARPins are fused to enve-
lope glycoproteins and therefore trafﬁc through the secretory
Figure 7. Correlation of the Binding and Surface-Expression Properties of the Selected GluA4-DARPins with Their Ability to Mediate Transduction
(A) Representative flow cytometry histograms showing the cell surface expression of GluA4-DARPin variants as indicated or the scFv Fab7 fused to the measles virus H
protein after transient transfection of HEK293T cells with the corresponding expression plasmids (black lines) compared to mock-transfected cells (filled curves). (B)
Transduction of CHO-aHis or CHO-GluA4 cells with DARPin-LV or Fab7-LV particles. Cells were analyzed for GFP expression 72 hr post-transduction by flow cytometry. The
dot plots shown are representative for three biological replicas. The percentage of GFP-positive cells is indicated. (C) Binding of increasing amounts of recombinant GluA4-Fc
protein to HEK293T cells expressing DARPin-H constructs as indicated or the Fab7-H protein on their surface. The mean fluorescence intensities (MFIs) of GluA4-Fc binding
for the complete cell population are plotted against the concentration of GluA4-Fc applied for binding. Data were fitted to a 1:1 Langmuir bindingmodel to determine apparent
binding avidity and maximal functional binding values. (D) Correlation of surface expression and GluA4 binding properties of DARPin-H fusion proteins with the DARPin’s
ability to mediate gene transfer. MFIs of stained cell population as shown in (A) are plotted against the maximal functional binding capacity (top) or apparent binding avidity
(bottom) as determined from curves shown in (C). Symbols indicate whether the DARPin enabled GluA4-targeted gene transfer for LVs and AAVs, only one of both, or none.
The dashed lines indicate gates for the clustering of DARPins. See also Figures S8 and S9.
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pathway thus being exposed to the glycosylating enzymes of the ER
and Golgi. In contrast, for re-targeting of AAV particles, DARPins
are N-terminally coupled to the capsid protein VP2, which is a cyto-
solic protein, routed to the nucleus for AAV assembly. Thus, only
DARPins used for LVs are exposed to glycosylation during transport
to the cell surface.
Binding afﬁnity is another important property of DARPins. To
reﬂect the physiological situation of vector particle production
and vector particle receptor interaction as close as possible, we
decided to measure the binding of soluble receptors to cells trans-
fected with expression plasmids encoding the DARPin-H fusion
proteins. While the results from this assay may not be comparable
to afﬁnities determined by surface plasmon resonance (SPR), they
provide at least relative values allowing us to better understand
the binding requirements. Our analysis suggested that functional
binding afﬁnity appears to be more relevant for AAVs than for
LVs. The lowest apparent avidity of DARPins compatible with
AAV was 4 nM and 30 nM for those compatible with LV. An
even lower afﬁnity threshold of about 106 M has been previously
determined for Her2-targeted MVs.36,37 MV particles are larger
than LV particles and likely contain more envelope proteins, thus
potentially allowing compensation of lower afﬁnities by higher avid-
ity. Moreover, MVs are replication competent, and once cells have
been entered mainly spread by cell-cell fusion, which can involve
even more envelope protein receptor pairs.
For AAV, the situation is totally different. Only up to ﬁve DARPins
can be displayed on a single AAV particle, which are at least
10-fold less than on LV.15 In addition, entry pathways differ substan-
tially: LV vectors rely on fusion at the cell membrane, while
AAVs require endocytosis.8 Receptor internalization is a rate-limiting
Figure 8. Selection of CD105 and NKp46-Specific DARPins for Receptor-Targeted Gene Transfer
B-N2C and B-N3C DARPin libraries were used to select binders specific for murine CD105 and DARPin libraries VV-N3C and S-N3C for the selection of binders specific for
the NK cell marker NKp46. (A and D) Crude E. coli extracts of randomly picked clones obtained as output of the ribosomal display selection procedure for CD105 (A) and
NKp46 (D) were analyzed for binding to HT1080 cells overexpressing the corresponding target receptor (HT1080-CD105, A; HT1080-NKp46, D) via flow cytometry. The
percentage of cells bound by the DARPin clone is shown. Arrows indicate selected DARPins used for further analysis. For CD105, 96 (A) and for NKp46, 22 (D) individual
E. coli extracts were analyzed. ctl, control E. coli extracts without DARPin. (B) 21 out of 96 identified CD105-binding DARPins were cloned into the expression plasmid
pDARPin-VP2 and used to produce CD105-targeted AAV particles encoding GFP for transduction of CD105-positive (CHO-mCD105) and -negative (CHO-K1) cells. Cells
were analyzed for GFP expression 72 hr post-transduction by flow cytometry. (C) Representative dot plots of four selected CD105-AAV particles from (B). The percentage of
GFP-positive cells is indicated. ut, untransduced cells. (E) 11 identified NKp46-binding DARPins were cloned into the expression plasmid pCG-HD18-DARPin. Surface
expression of the H-fusion proteins after transient transfection of HEK293T cells and binding of recombinant NKp46 were analyzed via flow cytometry. Correlation of the
surface expression of the corresponding DARPin-H fusion protein and binding to recombinant NKp46 is shown. DARPins used for gene transfer experiments in (F) are
indicated by rectangles. (F) HT1080-NKp46 and parental HT1080 cells were incubated with NKp46-DARPin displaying LV particles encoding GFP as indicated. Cells were
analyzed 72 hr after transduction by flow cytometry. The percentage of GFP-positive cells is indicated.
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process and can vary between receptors. Cellular contact of AAV par-
ticles therefore has to outlast receptor internalization for efﬁcient en-
try. In this respect, it will be important to determine if attachment of
the DARPin to its receptor is sufﬁcient or if secondary receptors like
the recently identiﬁed AAVR are required in addition for cell entry of
receptor re-targeted AAV vectors.38 Interestingly, DARPin 2K19,
which performed best on AAV, does not exhibit the highest func-
tional binding afﬁnity but, in contrast to all other DARPins, contains
only a single diversiﬁed repeat. Such small ankyrin repeat proteins
also occur naturally, although the majority possess two or three re-
peats.39 They are likely better compatible with assembly and the pack-
aging of genes into AAV particles considering that the DARPin likely
extrude from the pores at the ﬁvefold symmetry axis of the AAV
capsid.15 In order to still obtain sufﬁcient afﬁnity, such N1CDARPins
typically have binding sites rich in hydrophobic and aromatic resi-
dues (J. Schaefer, M. Schmid, and A.P., unpublished data), which
holds true for 2K19 as well (Figure S6).
GluA4, together with its closely related family members GluA1–3,
belongs to the AMPA (a-amino-3-hydroxy-5-methylisoxazole-
4-propionic acid) receptors and can form homo- as well as hetero-
mers.29 Inhibitory interneurons preferentially express GluA1 and
GluA4, while GluA1 and GluA2 are present on excitatory neurons,
at least in forebrain areas.40 Therefore, exclusive recognition of
GluA4 is required to target interneurons via AMPA receptors.
Notably, AMPA receptors share up to 90% sequence identity within
their LBDs and around 55% among their ATDs.41 From the selection
of phage-encoded antibodies against full-length GluA4 in proteolipo-
somes, it is known that cross-speciﬁc binders frequently occur.42 All
selected GluA4-DARPins enabling gene transfer by LV or AAV vec-
tors were highly speciﬁc for GluA4, showing no measurable cross
reactivity with the other AMPA family members. Interestingly,
DARPin SK14 showed some binding to GluA2, however, only
when puriﬁed protein from E. coli was tested. Its afﬁnity for GluA2
thus seems to be too low, however, to result in off-target transduction.
In summary, the data presented in this manuscript imply that target-
ing ligands for LV and AAV vectors can be efﬁciently selected from
DARPin libraries, when incorporating direct testing for gene delivery
into the screening workﬂow. The data moreover show that, especially
for AAV, the screening process on vector particles is important to
identify those DARPins mediating the highest gene-delivery rates.
This could suggest that, although technically challenging, cloning a
(pre-selected) DARPin library directly into AAV could be a reason-
able next step. The broad experience available with AAV peptide
display and shufﬂed libraries will be helpful in this respect.43,44 The
selection and screening system we present here is highly ﬂexible.
This was demonstrated by the successful selection of DARPins spe-
ciﬁc for three different receptors. The novel generated GluA4-speciﬁc
AAV and LV vectors will facilitate exploring the role of interneurons
within the brain upon speciﬁc manipulation as well as gene therapy
applications in epilepsy.45 CD105-targeted AAVs may become appli-
cable in tumor-targeted gene delivery,46 and LVs targeted to NK cells
via NKp46 could be applied in immunotherapy.47
MATERIALS AND METHODS
Plasmid Construction
To generate target proteins for ribosome display, the ATD of rat
GluA4 (residues 22–401; amino acid positions refer to UniProt:
P19493) was cloned in frame with the IgG signal peptide into the
mammalian expression plasmid pCMV-hIgGI-Fc-XP,48 providing a
C-terminal human IgG-Fc region, to obtain pGluA4-huFc. To allow
biotinylation of the protein, a C-terminal Avi tag was fused to the hu-
man IgG-Fc region behind a G4S linker via PCR (primers 1 and 2).
The PCR fragment was cloned into pGluA4-huFc and pCMV-
hIgGI-Fc-XP via NheI and BclI to obtain pGluA4-huFc-Avi and
phuFc-Avi, respectively. Plasmids encoding the extracellular domains
of CD105 (residues 28–581; UniProt: Q63961) and NKp46 (residues
21–255; UniProt: O76036) were generated analogously to GluA4.
Phusion High-Fidelity DNA polymerase (New England Biolabs,
Frankfurt, Germany) was used for PCR reactions. All primer se-
quences for plasmid construction are available in Table S2.
To allow biotinylation of the Avi tag during protein expression within
mammalian cells, the gene encoding for the BirA ligase was PCR
ampliﬁed from E. coli TOP10 DNA. Primers 3 and 4 were used to
obtain full-length BirA ligase behind a CMV promoter and an Ig
kappa chain signal sequence and primers 3 and 5 to generate a
BirA ligase additionally harboring a C-terminal ER retention signal
consisting of the amino acids KDEL. Both PCR fragments were
cloned into the mammalian expression plasmid pDisplay via XhoI
and SﬁI to obtain pDisplay-sBirA and pDisplay-BirAER, respectively.
For analysis of selected DARPin binders, DARPin DNA fragments
were cloned into the E. coli expression plasmid pQE-HisHA via SﬁI
and DraIII containing an N-terminal RGSHis6 tag followed by an
HA tag. The plasmid pQE-HisHA was derived from pDST6749,50
by oligo annealing of primers 6 and 7 as well as 8 and 9 and simulta-
neous insertion of the resulting two DNA fragments encoding for a
His tag, HA tag, restrictions sites, and stop codons in pDST67 via
EcoRI and PacI. In addition, DNA fragments encoding the DARPin
inserts were cloned into the mammalian expression plasmids pCG-
HD18-DARPin encoding the blinded MV H-protein in fusion with
a targeting domain and a C-terminal His tag,51 and pDARPin-VP2
encoding a targeting domain in fusion with HSPG-blinded VP2 pro-
tein15 via SﬁI and NotI. DARPins from the CD105 selection were
cloned into the pDST67 expression plasmid via BamHI and HindIII
and PCR ampliﬁed (primers 10 and 11) as SﬁI and NotI fragments
before cloning into pDARPin-VP2.
Cell Culture
HEK293T (ATCC CRL-11268), CHO-K1 (ATCC CCL-61), and
HT1080 (ATCC CCL-121) cells were cultivated in DMEM (Sigma-
Aldrich, Munich, Germany) supplemented with 10% fetal calf serum
(FCS; Biochrom, Berlin, Germany) and 2 mM L-glutamine (Sigma-
Aldrich, Munich, Germany). The cell lines CHO-GluA4, CHO-
GluA1, CHO-GluA2, CHO-GluA3, CHO-GluR6, and CHO-aHis
as well as CHO-CD105 were derived from CHO-K1 cells by LV
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transduction (see below) and cultivated in the same medium in pres-
ence of 10 mg/mL (CHO-GluA4) or 2 mg/mL (CHO-GluA1-3, CHO-
aHis) puromycin (Thermo Fisher Scientiﬁc, Darmstadt, Germany),
or 1.2 mg/mL (CHO-mCD105) G418 (Thermo Fisher Scientiﬁc,
Darmstadt, Germany). HT1080-NKp46 and HT1080-CD105 were
derived from HT1080 cells and cultivated in the same medium in
the presence of 400 mg/mL zeocin (InvivoGen, Toulouse, France) or
1.2 mg/mL G418, respectively. CHO-GluA4 cells were established
by LV transduction of CHO-K1 cells with LV particles having pack-
aged the coding sequence for GluA4 with an N-terminal myc tag.13
For generation of CHO cells expressing glutamate receptor GluA1
(UniProt: P23818), GluA2 (UniProt: P19491), GluA3 (UniProt:
P19492), or GluR6 (UniProt: P42260), the gene encoding for the cor-
responding glutamate receptor, including its native signal sequence in
case of GluR6 or the signal sequence of uridine diphosphate (UDP)-
glucosyltransferase in case of GluA1–3, was PCR ampliﬁed, thereby
adding an N-terminal FLAG tag and cloned into a bicistronic LV
transfer vector, encoding a spleen focus-forming virus (SFFV) pro-
moter, an internal ribosome entry site (IRES) element followed by a
puromycin resistance gene and a woodchuck posttranscriptional reg-
ulatory element (WPRE) via PacI and SpeI, resulting in the bicistronic
plasmids pS-GluA1-IPW, pS-GluA2-IPW, pS-GluA3-IPW, and pS-
GluR6-IPW, respectively. CHO-GluA1, CHO-GluA2, CHO-GluA3,
and CHO-GluA6 cells were established by LV transduction of
CHO-K1 cells with LV particles having packaged the glutamate-re-
ceptor-encoding constructs. CHO-aHis cells were established by
LV transduction of CHO-K1 cells with LV particles having packaged
the coding sequence for the anti-His scFv 3D532 fused to the trans-
membrane region of the platelet-derived growth factor receptor
(PDGFR). Transduced cells were selected using puromycin for
2 weeks. For the generation of HT1080 cells expressing NKp46, cells
were transduced with LVs having packaging the full-length receptor
in addition to the zeocin resistance marker. HT1080 and CHO cells
expressing full-length CD105 were generated by transient transfec-
tion and selection with 1.2 mg/mL G418.52
Recombinant Protein Production and Purification
Target proteins for ribosome display were expressed in HEK293T
cells by transient transfection using polyethylenimine (PEI) and
puriﬁed from the cell culture medium. For direct biotinylation of
the recombinant proteins during expression and after release into
the cell culture supernatant, plasmids encoding for the target protein
and pDisplay-sBirA and pDisplay-BirAER were used in a ratio 1:2:2.
Twenty-four hours before transfection, 1  107 cells were seeded
per T175 ﬂask. On the day of transfection, the cell culture medium
was replaced by 10 mL DMEMwith 15% FCS and 2 mM L-glutamine
(DMEM + FCS). For the transfection mix, 35 mg of total DNA was
mixed with 2.3 mL of DMEM without additives and added to
2.2 mL DMEM supplemented with 140 mL of 18 mM PEI solution.
After incubation for 20 min at room temperature, the transfection
mix was added to the HEK293T cells. 24 hr later, the medium was re-
placed by 20 mL DMEM supplemented with 5% Panexin NTA (Pan
Biotech, Aidenbach, Germany) and 2 mM L-glutamine with or
without 10 mM biotin per T175 ﬂask. At day 2 post-transfection,
cell supernatants containing the recombinant protein were passed
through a 0.45-mm pore size ﬁlter and puriﬁed on Protein A-Sephar-
ose (Thermo Fisher Scientiﬁc, Darmstadt, Germany) columns ac-
cording to the manufacturer’s recommendation. In brief, 200 mL of
Protein A-Sepharose beads were incubated with 200 mL cell culture
supernatant overnight at 4Cwith shaking. On the next day, the beads
were collected and washed with 20 mL PBS, before elution of the re-
combinant proteins with 5 mL of 100 mM glycine (pH 2.7). To
neutralize the acidic pH, 1/10 volume of 1 M Tris (pH 8.8) was
directly added to the eluted protein fractions. As a further polishing
step, size-exclusion-chromatography was performed with the eluted
recombinant proteins using a Superdex 200 HighLoad 16/600 column
(GE Healthcare, Germany) in a high-pressure liquid chromatography
(HPLC) system (ÄKTAxpress, GE Healthcare, Germany) according
to the manufacturer’s instructions using PBS as running buffer.
Fractions containing the recombinant protein were pooled and
concentrated using 50-kDa cut off spin concentrators. The concen-
trated protein was supplemented with 5% glycerol and protease
inhibitor (cOmplete ULTRA, Roche, Mannheim, Germany) and
stored at 80C. Protein concentrations were determined by
Bradford assay. For CD105, biotinylation was performed as previ-
ously described.53
Determination of Protein Biotinylation via ELISA
To determine the content of biotinylated GluA4-Fc protein within the
protein preparation, 96-well Maxisorb plates (Nunc as part of
Thermo Fischer Scientiﬁc, Darmstadt, Germany) were coated with
graded amounts (0–44.6 pmol) of biotinylated and unbiotinylated
GluA4-Fc and standard protein (MBP-Avitag fusion protein stan-
dard, BIS-300, Avidity, Aurora, Colorado, USA) in PBS. Coating
was performed for 1 hr at room temperature. After washing the wells
four times with 300 mL PBS-T (0.05% Tween 20 in PBS), unspeciﬁc
binding was blocked by addition of 300 mL PBS-TB (0.5% BSA in
PBS-T) per well for 1 hr at room temperature. Wells were washed
four times with 300 mL PBS-T before incubation with horseradish
peroxidase (HRP)-coupled streptavidin (1:500; 016-030-084, Jackson
ImmunoResearch, West Grove, PA, USA) for 1 hr at room tempera-
ture. After washing the wells four times with PBS-T, the bound strep-
tavidin was detected using SureBlue TMB substrate (KPL as part of
SeraCare, Milford, MA, USA) and 1 N H2SO4. The reaction product
was quantiﬁed in a microtiter plate reader at 450 nm.
DARPin Library Generation
The DARPin library was assembled repeat-by-repeat on the basis of
previously described protocols.20,21 In brief, a DNA library encoding
one internal designed Ankyrin repeat diversiﬁed at seven amino acid
positions as well as the constant N- and C-cap gene fragments were
codon optimized for expression in E. coli and de novo synthesized
by GeneArt. The DNA and amino acid sequence of the de novo syn-
thesized DNA fragments is available in Table S3 and Figure S1A,
respectively. The consensus sequence of the internal repeat and
capping fragments was previously described.23 In the ﬁrst assembly
step, the N-cap and the internal repeat, were digested using the
type II restriction enzymes BsaI and BbsI, respectively, ligated, gel
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puriﬁed, and PCR ampliﬁed (primers 1 and 2). Vent DNA Polymer-
ase (New England Biolabs, Frankfurt, Germany) was used for PCR re-
actions. All primer sequences for DARPin library generation are
available in Table S4. The puriﬁed PCR product was used as starting
material for the next assembly round with another internal repeat. Af-
ter the addition of two or three internal repeats to the N-cap fragment,
the DARPin library was ﬁnalized by ligation of the C-cap fragment,
PCR ampliﬁcation (primers 3 and 4) and gel puriﬁcation, resulting
in a high-quality N2C and N3C DARPin library encoding approxi-
mately 1.8  1013 and 1.4  1013 diversiﬁed DARPin molecules,
respectively. In a last step, the DARPin libraries were N-terminally
ﬂanked with a T7 Promoter, a ribosomal binding site, and a His
tag, and C-terminally with a spacer sequence derived from TolA to
allow in vitro transcription and the formation of a ternary complex
of mRNA, ribosome, and the DARPin protein. The N- and C-termi-
nal fragments were generated by PCR (primers 4 and 5; primers 7
and 8) using the pRDV plasmid as template.54 After restriction of
the N-terminal fragment with SﬁI, the C-terminal fragment with
DraIII and the DARPin library with SﬁI and DraIII, the three frag-
ments were ligated, gel puriﬁed, and PCR ampliﬁed using primers 9
and 10. The puriﬁed PCR product was used as starting material for
ribosome display. Diversity of the assembled library and of each inter-
mediate product was estimated from the amount of ligated DNA
recovered after gel puriﬁcation before PCR ampliﬁcation (Table S1).
Ribosome Display
Ribosome display selections were carried out as previously described
with somemodiﬁcation as indicated.53 In brief, each ribosome display
selection started with the coupled transcription and translation of
DARPin libraries using the PURExpress in vitro synthesis kit (New
England Biolabs, Frankfurt, Germany). For one coupled transcription
and translation reaction, up to 100 ng DNA, 4 mL solution A, 3 mL so-
lution B, and 0.4 mL RiboLock were incubated for 2 hr at 37C in a
total volume of 10 mL before adding 225 mL STOP mix (50 mM
Tris-Ac [pH 7.5], 150 mM NaCl, 50 mM MgAc, 2.5 mg/mL heparin,
50 mg/mL Saccharomyces cerevisiae RNA). The produced ternary
complexes of RNA, ribosomes, and DARPin proteins were subse-
quently subjected to pre-panning steps with 20 mM immobilized
neutravidin or streptavidin per well as well as 20 mM immobilized re-
combinant Fc protein before being co-incubated with 40 mM of im-
mobilized target proteins. After washing away non-binders, the
bound ternary complexes were eluted and the puriﬁed mRNA
(RNeasy Mini Kit; QIAGEN, Hilden, Germany) reverse transcribed
using the AfﬁnityScript Multiple Temperature Reverse Transcriptase
(Agilent, Santa Clara, CA, USA) for 60 min at 50C after primer an-
nealing for 5 min at 95C. The resulting DARPin DNA pool was
ampliﬁed using primers 3 and 4 for the VV-N2C and VV-N3C li-
braries and primers 11 and 12 for the S-N3C library, ﬂanked with
N- and C-terminal fragments as described above and used as starting
material for the next round of ribosome display. After three selection
rounds on immobilized target proteins, two off-rate selection rounds
with target in solution were performed using 6.5 pmol of biotinylated
GluA4-Fc or Fc protein and 65 pmol of unbiotinylated GluA4-Fc
protein. After the last selection round, DNA fragments encoding
DARPin inserts were subjected to single clone-screening assays (see
below). For the selection of CD105-speciﬁc DARPins, a separate tran-
scription and translation reaction as well as error-prone PCR were
performed using the N2C and N3C DARPin libraries, here termed
B-N2C and B-N3C, described by Binz et al.20, according to previously
published protocols.53
Crude E. coli Extracts and Sequence Analysis
Single selected DARPins were expressed in 96-deep-well plates as
described before with the exception that the expression vector pQE-
HisHA was used instead of pDST67 for GluA4 and NKp46 selected
DARPins.50,53 In brief, DNA fragments encoding the DARPin inserts
were subcloned into the expression vector pQE-HisHA via SﬁI and
DraIII and used for transformation of E. coli XL1-blue bacteria. For
screening of single clones, randomly picked colonies were subjected
to DNA sequencing using standard techniques and used to inoculate
600 mL 2YT expression medium (2YT, 1% glucose, 100 mg/mL ampi-
cillin) at 37C. On the next day, 900 mL fresh 2YT expression medium
was inoculated with 100 mL overnight culture for 1 hr at 37C before
addition of 100 mL of 5.5 mM isopropyl-b-D-thiogalactopyranosid
(IPTG) in 2YT medium to each well and subsequent incubation at
37C for 5 hr. All liquid cultures were incubated with shaking. After
harvest by centrifugation, bacteria pellets were stored at 80C.
Thawed bacteria pellets were resuspended in 50 mL B-PER II (Thermo
Scientiﬁc, Dreieich, Germany) before incubation at room tempera-
ture for 2 hr on an orbital shaker. After addition of 450 mL
Tris-buffered saline (TBS) per well, cell debris was removed from
crude extract by centrifugation. Crude extracts were aliquoted and
stored at 80C.
Small-Scale Purification of DARPins
E. coli XL-1 blue bacteria (Stratagene, San Diego, CA, USA)
were transformed with pQE-HisHA plasmids containing selected
DARPins. A single colony was used to inoculate 6 mL lysogeny
broth (LB) expression medium (LB, 1% glucose, 100 mg/L ampi-
cillin) at 30C. On the next day, 5 mL overnight culture was used
to inoculate 100 mL LB expression medium at 37C. At an optical
density (OD A600) of 0.7, the cultures were induced with 300 mM
IPTG and incubated for 4 hr at 37C. All liquid cultures were incu-
bated with shaking. After harvest, cells were suspended in 4 mL lysis
buffer (50 mM Tris [pH 8.0], 500 mM NaCl) before cell disruption
was performed by sonication for 4 min. After removal of cell debris
by centrifugation at 17,000  g for 15 min, lysis buffer was added to
the cleared lysate to generate a total volume of 5 mL. Before puriﬁ-
cation of DARPins on Ni-nitrilotriacetic acid (NTA) Agarose (-
QIAGEN, Hilden, Germany) columns according to the manufac-
turer, 3.5 mL 2.5 glycerol buffer (50 mM Tris [pH 8.0],
500 mM NaCl, 25% glycerol, 50 mM imidazole) was added to the
lysates. Fractions containing the recombinant protein were pooled
and dialyzed against PBS using 3.5 kDa molecular weight cut-off
(MWCO) dialysis tubing. The dialyzed protein was supplemented
with 5% glycerol and protease inhibitor (cOmplete ULTRA, Roche,
Mannheim, Germany) and stored at 80C. Protein concentration
was determined by Bradford assay.
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SDS-PAGE Analysis by Coomassie Staining and Western Blot
Proteins were incubated with 1 SDS-sample buffer (60 mM Tris
[pH 6.8], 2% SDS, 10% glycerol, 5% b-mercaptoethanol, 0.015%
bromophenol blue) at 95C for 10 min and loaded on 10% or 15%
SDS-PAGE gels as indicated. After electrophoretic separation,
SDS-PAGE gels were either directly stained with PageBlue Protein
Staining Solution (Thermo Fisher Scientiﬁc, Dreieich, Germany)
according to the manufacturer, or proteins were blotted on
nitrocellulose membranes.
The membranes were incubated with mouse anti-RGS-His4 (1:1,000;
34650, QIAGEN, Hilden, Germany) and HRP conjugated rabbit anti-
mouse (1:2,000; P0260, DAKO as part of Agilent, Santa Clara, CA) or
HRP conjugated goat anti-human IgG (1:50,000; A0170, Sigma-Al-
drich, Munich, Germany) or HRP conjugated streptavidin (1:5,000;
016-030-084, Jackson ImmunoResearch, West Grove, PA, USA). Sig-
nals were detected using the ECL Plus Western Blotting Detection
System according to the manufacturer (Thermo Fisher Scientiﬁc,
Dreieich, Germany). All antibodies were diluted in TBS-T (50 mM
Tris, 150 mM NaCl, 0.1% Tween-20, pH 7.4) containing 2%
powdered milk.
Vector Production
LV and AAV vector particles were generated by transient transfection
using PEI as described above. In brief, 24 hr prior to transfection,
4 105 HEK293T cells were seeded per 12-well. On the day of trans-
fection, the cell culture medium was replaced by 400 mL DMEM +
FCS. For the transfection mix, 802 ng of total DNA was mixed with
53 mL of DMEM without additives and added to 50 mL DMEM sup-
plemented with 3 mL of 18 mM PEI solution per 12-well plate. After
incubation for 20 min at room temperature, the transfection mix was
added to the HEK293T cells. 24 hr later, the medium was replaced by
750 mL fresh cell culture medium. At day 2 post-transfection, cell su-
pernatants containing the vector particles were collected and centri-
fuged for 5 min at 1,000  g to remove cell debris. The vector stocks
were stored at 4C (LV vector stocks max. 1 day; AAV vector stock
max. 2 weeks).
For LV-targeting vectors, 30.9 ng of pCG-HD18-DARPin plasmid,
92.5 ng of pCG-FcD30 plasmid encoding MV F protein,55 331.0 ng
of the packaging plasmid pCMVDR8.9,56 and 347.6 ng transfer vector
pSEW encoding GFP as reporter57 were used for transfection. LV par-
ticles pseudotyped with the vesicular stomatitis virus glycoprotein
(VSV-G) were produced by co-transfection of 140.4 ng pMD.G258
along with 260.7 ng pCMVDR8.9 and 401.0 ng pSEW.
AAV-targeting vectors and AAV-2 were generated using the adeno-
virus-helper-free AAV-packaging strategy.59 For AAV-targeting vec-
tors, 401.0 ng of the helper plasmid pXX6-80, 133.7 ng of the
pRCVP2koA plasmid encoding rep and cap proteins of AAV-2
deleted for HSPG binding and mutated VP2 start codon,15 133.7 ng
of the pDARPin-VP2 plasmid, and 133.7 ng of the self-complemen-
tary transfer vector pscGFP encoding GFP as reporter14 were trans-
fected. AAV-2 vector particles were produced by co-transfection of
481.2 ng pXX6-80 plasmid, 160.4 ng of the pRC plasmid encoding
rep and cap proteins of AAV-260, and 160.4 ng pscGFP.
Transduction of Cell Lines and Flow Cytometry Analysis
For transduction, 3 108 cells of indicated cell lines were seeded into
a single well of a 96-well plate. Twenty-four hours later, the cell cul-
ture medium was exchanged by 50 mL targeting-vector stock per well.
After 2 hr, 150 mL cell culture medium was added per well. VSV-G-
LVs and AAV-2 vectors were 1:50 and 1:5 diluted in 50 mL cell culture
medium, respectively, prior to cell transduction. At day 3 post-trans-
duction, transduced cells were determined by ﬂow cytometry analysis
based on the indicated percentage of green ﬂuorescent cells. Flow cy-
tometry analysis was performed on the MACSQuant Analyzer 10
(Miltenyi Biotec, Bergisch Gladbach, Germany). Data were analyzed
using FCS Express version 4.0 (DeNovo Software).
Binding Assays and Surface Expression
For binding experiments of crude DARPin extracts as well as puriﬁed
DARPins to target-positive and -negative cells, 1  105 cells were
washed twice with FACS washing buffer (PBS, 2% FCS, 0.1%
NaN3) before incubation with 10 mL crude DARPin extracts or
5 mg of puriﬁed DARPin proteins for 1 hr at 4C, respectively. After
two additional washing steps, cells were stained with an Alexa 488-
labeled anti-PentaHis antibody (1:330; 35310, QIAGEN, Hilden, Ger-
many) for 15 min at 4C if crude DARPin extracts were used or with a
phycoerythrin (PE)-labeled anti-HA antibody (1:100; 130-092-257,
Miltenyi Biotec, Bergisch Gladbach, Germany) for 30 min at 4C in
the case of puriﬁed DARPins. Before ﬂow cytometry analysis, cells
were washed again and resuspended in 100 mL FACS ﬁxation buffer
(PBS, 1% formaldehyde).
To analyze the surface expression of DARPin constructs displayed as a
fusion to MV H-protein and their binding to recombinant GluA4,
HEK293T cells were transfected with the corresponding pCG-HD18-
DARPin expression plasmid. After 48 hr, 1  105 transfected cells
werewashed twicewith FACSwashing buffer and either directly stained
with a PE-labeled anti-His antibody (1:100; 130-092-691,Miltenyi Bio-
tec, Bergisch Gladbach, Germany) for 30 min at 4C to determine the
DARPin-H surface expression or incubated with increasing amounts
of recombinant GluA4-huFc proteins (0–70 nM recombinant
protein in up to 1 mL buffer) for 60 min at 4C and a ﬂuorescein
isothiocyanate (FITC)-labeled anti-human Fc antibody (1:100; 2043-
02, SouthernBiotech, Birmingham, AL, USA) with two washing steps
in between. At an estimated receptor density of up to 1 105 receptors
molecules per transfected cell,18 ligand depletion can be excluded
for all dilutions up to 0.017 nM. After two additional washing steps,
cells were resuspended in FACSﬁxation buffer and subjected toﬂow cy-
tometry analysis. Apparent binding avidity and functional binding ca-
pacity values were determined by ﬁtting the curves to a 1:1 Langmuir
binding model using Prism 7 software (GraphPad). To determine the
surface expression and binding capacity of selected NKp46-speciﬁc
DARPins, they were expressed as H fusion protein in HEK293T cells
and detected via the His tag or incubated with 5 mg recombinant
NKp46, respectively.
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Competition Assay
50 mL of targeted LV and AAV vectors as well as 1 mL VSV-G-LVs
and 10 mL AAV-2 in a total volume of 50 mL were pre-incubated
with 2.2 mg of recombinant GluRD-Fc, 1.1 mg of Fc protein, or 2 mL
PBS for 1 hr at 4C, respectively. Afterwards, CHO-GluA4 and
CHO-K1 were transduced with pre-incubated vector stocks before
GFP expression was analyzed after 72 hr by ﬂow cytometry.
ELISA-Based Binding Assay
96-well Maxisorb plates (Nunc as part of Thermo Fisher Scientiﬁc,
Dreieich, Germany) were coated with 100 mL 20 mM Neutravidin
solution in TBS for 1 hr at room temperature. After washing the
wells three times with 300 mL TBS-T, unspeciﬁc binding was
blocked by addition of 300 mL TBS-TB for 1 hr at room temperature.
To immobilize the target protein, wells were incubated with 70 ng of
biotinylated GluA4-Fc protein for 1 hr at 4C on an orbital shaker.
After three additional washing steps, wells were incubated with
graded amounts of DARPin proteins (0–10 pmol/well) for 1 hr at
4C on an orbital shaker. At the used ligand concentrations and vol-
umes, ligand depletion could be excluded for concentrations
R25 nM. To quantify the amount of bound DARPin proteins, wells
were subsequently incubated with a mouse anti-RGS-His4 antibody
(1:5,000; 34650, QIAGEN, Hilden, Germany) and anHRP conjugated
rabbit anti-mouse antibody (1:2,000; P0260, DAKO as part of Agilent,
Santa Clara, CA) for 1 hr at room temperature. The plates were
washed three times with TBS-T before and after each antibody incu-
bation step. The bound antibodies were detected using SureBlue TMB
substrate (KPL as part of SeraCare, Milford, MA, USA) and 1 N
H2SO4. The reaction product was quantiﬁed in a microtiter plate
reader at 450 nm. The apparent binding afﬁnity was determined by
ﬁtting the curves to a 1:1 Langmuir binding model using Prism 7 soft-
ware (GraphPad).
Statistical Analysis
Statistical analyses were performed with Prism 7 software (GraphPad).
Tests for statistical signiﬁcance used the unpaired two-tailed Student’s
t test or one-way ANOVA (Tukey’s multiple comparisons test) as indi-
cated; p values less than 0.05 were considered signiﬁcant.
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